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Dengue Fever (DF), transmitted by Aedes mosquitoes, 
is the most common arthropod-borne infection. It is 
almost ubiquitous in tropical and subtropical areas 
with an estimate of 360 million infections per year. 
A competent vector (A. albopictus) is present in most 
of Southern Europe and is endemic in Italy. We con-
ducted a 16-year retrospective study of probable/
confirmed dengue fever observed at the Department 
of Infectious Diseases of Luigi Sacco Hospital in Mi-
lan, Italy. Overall 122 patients were included in the 
study, 106 with probable and 16 with proven diagno-
sis of dengue fever. Most patients (91%) were Italian, 
with a median age of 35 years (IQR 29-46 years) and 
similar gender distribution, travelling for tourism 
(80%). Asia (mainly South East Asia and Indian Sub-
continent) was the most frequent travel destination 
(55%), followed by Central America and the Caribbe-
ans (22%). August-September was the peak season of 
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presentation (42.6%). The majority of our diagnoses 
were based on serology alone. The most common 
signs and symptoms were fever (99,2%), maculo-
papular rash (50,8%), headache (50,8%), arthralgias 
(50,8%) and myalgias (46,7%). Leukopenia (77%), 
thrombocytopenia (81%) and altered LDH, AST and 
ALT (respectively 60,6%, 54,1% and 45,9%) were the 
most common laboratory test’s abnormalities. No 
cases of severe DF were recorded. Our epidemiolog-
ical and clinical findings are largely in accordance 
with most recent studies about imported DF in Eu-
rope. Although very similar in presentation to other 
arthropod-borne illnesses, some clinical features may 
help in differentiating DF from other causes of fever 
in the returning traveler.
Keywords: Dengue, dengue fever, arboviral infections, 
imported infections, travel medicine.
n INTRODUCTION
Dengue fever is caused by a single-stranded RNA virus belonging to Flaviviridae (Dengue 
virus), subdivided in four closely related, but anti-
genically different, serotypes (DENV 1-4).
Dengue fever is the most common arthro-
pod-borne viral infection worldwide and an in-
creasingly recognized public health problem. It is 
endemic in more than one hundred tropical and 
subtropical countries and 2.5 billion people are at 
risk of transmission, the greatest disease burden 
being observed in Central and South America and 
Southern and South-Eastern Asia. According to 
recent estimates there are as much as 360 million 
infections per year (96 million of which clinically 
evident) [1-3].
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Infection with one serotype grants permanent 
immunity against the same serotype, but only 
temporary protection against the others. Aedes 
mosquitoes are the vectors of the infection, which 
is most efficiently transmitted by A. aegypti, an 
urban day-biting tropical mosquito, and less fre-
quently by A. albopictus or other species [4]. 
Clinical manifestations range from a self-limiting 
febrile flu-like disease (non-severe dengue) to a 
severe and potentially fatal syndrome character-
ized by capillary leak syndrome (possibly lead-
ing to shock), end-organ failure and haemorragic 
manifestations (severe dengue), the latter more 
common in secondary infections [4].
Dengue is recognized as a frequent cause of mor-
bidity in international travelers, being the most 
common cause of fever in travelers returning 
from South and Southeast Asia and Latin Amer-
ica [5]. Due to the presence of the virus in some 
of the most popular tourism destinations and to 
the increase in trans-continental travelling, a ris-
ing number of imported cases of Dengue has been 
reported in Europe [6-9].
At present there is concern regarding the possi-
ble reintroduction of dengue fever in Southern 
Europe, where several international airports are 
located in areas where a competent vector (i.e., A. 
albopictus, commonly known as the “Asian Tiger 
Mosquito”) is widespread [10, 11]. As a matter of 
fact, several cases of autochthonous transmission 
have already been reported in France, Spain and 
Croatia and a recent outbreak (sustained by A. 
aegypti transmission) occurred on the Portuguese 
island of Madeira in 2012-2013, with more than 
2200 infections [12-16]. 
We aimed to analyze the epidemiological and 
clinical features of imported dengue fever (DF) 
observed at Luigi Sacco Hospital’s Department of 
Infectious diseases in Milan (Italy) over a 16-years 
period. 
n PATIENTS AND METHODS
A retrospective study was carried out at the Lui-
gi Sacco Hospital from January 2001 to Decem-
ber 2016. This university-affiliated hospital is a 
referral center for imported tropical infections in 
Northern Italy.
Patients were selected using two complementary 
methods: all the patients whose discharge diag-
nosis codec according to the International Classi-
fication of Diseases, ninth Revision [ICD-9], cor-
responded to “dengue fever” and cross-checked 
with Microbiology’s electronic archive for pa-
tients with positive serologies for DENV antibod-
ies and/or positive PCR for DENV, were included 
in the analysis. 
Clinical data were subsequently retrieved from 
their clinical records and anonymized. The fol-
lowing parameters were recruited: personal data 
(age, gender, nationality), year and month of 
admission and discharge, diagnosis, country of 
origin, visited countries, reason of travel, trav-
el period (dated of beginning and end of travel, 
travel duration), signs and symptoms at presenta-
tion and their onset date, comorbidities, haema-
tologic and biochemical tests’ results (complete 
blood count, creatinine, blood glucose, blood urea 
nitrogen (BUN), lactate dehydrogenase (LDH), 
transaminases, blood bilirubin, gamma glutamyl 
transpeptidase (gGT), prothrombin and activated 
tromboplastin time (as normalized ratios), serol-
ogies for DENV (IgM and IgG class antibodies).
Definitions
According to CDC definitions a case of “prob-
able” DF was defined as a positive serology for 
DENV together with compatible clinical and epi-
demiological features; a case of “proven” DF was 
defined as a positive PCR for DENV RNA or at 
least a fourfold increase in IgG titer between se-
rum samples withdrawn during the acute phase 
and the convalescent phase (17).
Travel destinations were grouped under five ar-
eas: A (Asia and Southeast Asia), B (Oceania), C 
(Africa and Middle East), D (Central America and 
Caribbean), E Area (South America).
Leukopenia was defined as a white cell count 
≤4000 cells/µL (neutropenia as a neutrophil count 
≤1500 cells/µL), thrombocytopenia as a platelet 
count ≤150.000 cells/µL.
Altered values were defined if >220 IU/L for 
LDH, >35 IU/L for AST, >40 IU/L for ALT.
Diagnostic Methods
Research of DENV specific antibodies was per-
formed by commercially available Dengue virus 
specific IgM and IgG detection kit (NovaLisa Den-
gue IgG/IgM ELISA, Immunodiagnostica Gmbh, 
Dietzenbach, Germany) according to manufactur-
er’s instructions. From 2015 on, real-time reverse 
transcription polymerase chain reaction (RT-PCR) 
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for DENV-RNA was performed by means of a 
commercially available kit (Dengue/CHICKV 
RT-PCR, Fast Track Diagnostics Ltd., Malta).
Review Methods
The PubMed and Google Scholar databases were 
searched for articles in English, published between 
2004 and 2017 using the following combination 
of MESH terms: “dengue”, “imported” and “Eu-
rope”. We then selected epidemiological studies 
about imported DF set in European countries.
Statistical methods
Continuous variables were described as median 
and interquartile range (IQR).
Discrete variables were described as absolute 
number and percentage.
Patients were also divided in two groups based on 
the time elapsed between the onset of symptoms 
and hospital admission (equal or less than 4 days 
and more than 4 days): Wilcoxon-Mann-Whitney 
Test was used to compare continuous variables 
between two groups.
A p-value <0.05 was considered significant.
n RESULTS
A total of 122 patients observed between 2001 
and 2016 were included. We did not observe an 
increasing trend in the number of diagnosed cases 
over the period of study (Figure 1).
The majority of patients were young (median 
age: 35 years; IQR 29-46) and Italian (91%). Males 
and females were almost equally represented 
(M:F=1:1,07) (Figure 2). One hundred and six 
patients had “probable” DF and 16 fulfilled a di-
agnosis of “proven” DF. The median duration of 
travel was 18 days (RIQ 14-25).
Tourism was the main reason of travel (n=97; 
80%), 12 patients (10%) were travelling for work-
ing reason, 9 (7,5%) were visiting friends or rela-
tives (VFR). Four patients were travelling for oth-
er reasons (volunteering, religious missions, etc.). 
More than half of the patients (n=67; 55%) were 
returning from Asia, 27 (22%) were returning 
from the Central America/Caribbean area, 16 
(13%) from South America, 9 (7%) from Africa 
or the Middle East and two (2%) from Oceania. 
Travel destination was unknown for one patient. 
Absolute and relative frequencies for destination 
areas are shown in Figure 3. Reported travel desti-
nations for each patient are shown in Table 1.
Almost half (n= 52, 43%) of the patients were ob-
served in August and September (see Figure 4 for 
the distribution during the rest of the year).
In more than half of the patients (n=71; 58.2%) 
the onset of symptoms occurred from three days 
before to three days after the return from the en-
demic area. The median time interval between 
symptoms onset and hospitalization was 4 days 
(RIQ 3-6). Demographics and travel characteris-
tics (compared with the ones observed in recent 
studies about imported Dengue in Europe) are 
shown in Table 2.
The majority of patients (n=115, 94.3%) had de-
tectable IgM antibodies against DENV at the time 
of hospital presentation. More specifically, 35 pa-
tients (28,7%) had positive serology for both IgM 
Figure 1 - Dengue Fever cases 
observed at Luigi Sacco Hospi-
tal’s Department of Infectious 
Diseases, 2001-2016.
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and IgG antibodies, 80 (65.6%) only for IgM class. 
Six (4.9%) had initially negative serology. In the 
latter group diagnosis was established either with 
PCR or serological follow-up. In one (0.8%) pa-
tient diagnosis was obtained by detection of NS1 
antigen in a foreign hospital while abroad.
Overall, PCR for DENV was positive in 15 pa-
tients, with serotype identification in 7 cases: 4 
DENV-1 (from Mexico, Thailand, Sri Lanka and 
Congo), 2 DENV-2 (from China and the Philip-
pines) and 1 DENV-4 (from Thailand).
All patients were symptomatic at presentation, with 
Figure 2 - Distribution 
of Dengue cases by age 
and gender.
Figure 3 - Geographical distribution of imported Dengue Fever cases. The figure shows absolute number (col-
umns) and percentage (pie-chart).
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Table 1 - Reported travel destination(s) of patients affected by Dengue Fever.
Destination n %
ASIA 67 55.74
Thailand 22 18.85
India 12 9.84
Indonesia 5 4.10
Sri Lanka 4 3.28
Sri Lanka + Maldives 3 2.46
Philippines 3 2.46
Bali 2 1.64
Cambodia 2 1.64
Bangladesh 2 1.64
Laos + Cambodia + Thailand 2 1.64
Maldives 1 0.82
Thailand + Cambodia 1 0.82
Indonesia + Malesia + Singapore 1 0.82
Laos + Cambodia 1 0.82
Malesia 1 0.82
Myanmar 1 0.82
Myanmar + Cambodia + Thailand 1 0.82
Pakistan 1 0.82
Thailand + Malesia 1 0.82
Thailand + Singapore + Maldives 1 0.82
CENTRAL AMERICA and CARIBBEANS 27 22.13
Mexico 8 6.56
Dominican Republic 6 4.92
Cuba 5 4.10
Destination n %
Costa Rica 2 1.64
Haiti 2 1.64
Barbados 1 0.82
Cuba + Dominican Republic 1 0.82
Guadalupe 1 0.82
Grenada 1 0.82
SOUTH AMERICA 16 13.11
Brazil 8 6.56
Venezuela 3 2.46
Ecuador 3 2.46
Ecuador + Colombia 1 0.82
Colombia 1 0.82
AFRICA and MIDDLE EAST 9 7.38
Congo 1 0.82
Saudi Arabia 1 0.82
Cameroon 1 0.82
Eritrea 1 0.82
Mali 1 0.82
Nigeria 1 0.82
Kenya 1 0.82
Seychelles 1 0.82
Zanzibar (Tanzania) 1 0.82
OCEANIA 2 1.64
Polinesia 2 1.64
TOTAL 121†
†: data based on 121 patients, no data available about travel destination in one patient
Figure 4 - Distribution of 
dengue fever cases per 
month, 2001-2016
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fever observed in almost everyone (121; 99%); as-
sociated symptoms were as follow: maculopapular 
rash (62; 50.8%), headache (62; 50.8%), arthralgia 
(62; 50.8%), myalgia (57; 46.7%), nausea (32; 26.2%), 
vomiting (18; 14.8%) and diarrhea (22; 18%).
Signs and symptoms are reported in Table 3, com-
pared with the ones observed in recent studies 
about imported Dengue in Europe.
Laboratory findings are presented in Table 4; 
thrombocytopenia (99; 81%) and leukopenia 
(94; 77%) were the most common laboratory al-
terations observed on admission. Elevation of 
transaminases (AST>ALT) and lactate dehydro-
genase were other notable features.
We divided the patients in two groups, according 
to the time elapsed between the onset of symp-
toms and hospitalization (equal or less than 4 days 
and more than 4 days) and compared laboratory 
values between the two groups. Statistically sig-
nificant differences (p<0.05) were found between 
the two groups for absolute neutrophil count 
(1530 vs 1109/µL, p=0.026), absolute lymphocyte 
count (749 vs 1041/µL, p=0.018) and SGPT values 
(35 vs 61 UI, p=0.002).
n DISCUSSION
Dengue fever represents a raising concern in 
Southern Europe as a consequence of increased 
tourism to endemic areas and the widespread dif-
Table 2 - European literature review: traveler’s demographics and travel characteristics.
Author, reference
Present 
work
Teichmann 
[20] 
Laferl 
[21] 
Vinner 
[22]
Lagi 
[28]
Trojanek 
[23]
Hoffmeister 
[24]
Tavakolipoor 
[25]
Calleri 
[26]
Kuna 
[27]
Riddell 
[29]
Year of publication 2020 2004 2006 2012 2014 2015 2015 2016 2016 2016 2017
Country IT D A DK IT CZ D D IT PL UK
Study period 2001-2016 1993-2001 1990-2005 2001-2009 2006-2012 2004-2013 1996-2010 2007-2011 2010-2015 2010-2015 2010-2015
PATIENTS (N) 122 71 93 95 36 132 56 119 113 65 44
Age, year (median) 35 34 32.5 35.5 39 33 35 35 34 38 34
M:F 0.93:1 1.37:1 1.16:1 1.18:1 4.14:1 1.69:1 0.8:1 1.28:1 0,94:1 2,42:1 2,14:1
Europeans: 
Extra-europ.
10.09:1 NA‡ 9.33:1 NR 6.2:1 NR 3.67:1 NR NR NR NR
Hospitalized (%) 71.3 81.6 68 NR NR 38.6 NA§ 17.8 57,5 NA§ NR
DESTINATION (%)
Asia 54.9† 77.5 74 85 50 88 74a 73.1 49,6 44,6 70,4
Central America 22.1† 11.3 7.50 8.40 27.80 3.78 11b 4.2 39,8b 4,6 11,4
South America 13.1† 8.4 5.30 2.10 13.90 6 b 9.2 b 7,6 11,4
Africa 7.4† 1.4 10 4.20 2.80 0.80 9c 12 7,1 19 4,5
Oceania 1.6† 1.4 3.20 0 5.50 0 a 1 0 0 0
REASON FOR TRAVELLING (%)
Tourism 80.1 95.8 NR NR 63.90 71.20 NR 76.1 NR 26,1 NR
Work 9.9 4.2 NR NR 13.90 25 NR 8.5 NR 35,3 NR
VFR 7.4d 0 10 NR 19.40 3.80 NR 0.8 NR NR NR
TRAVEL CHARACTERISTICS
Duration 
(median days)
18 29 23.5 NR NR 21 NR 21 NR 924# NR
Ill before 
return (%)
36.8 28.2 58 NR NR 50.80 NR NR NR NR NR
M: F: male to female ratio; VFR: visiting friends and relatives; IT: Italy; A: Austria; DK: Denmark; CZ: Czech Republic; D: Germany; UK: United 
Kingdom; aWHO “Western Pacific” + “Southeast Asia” regions; bWHO “Americas” Region; cWHO “African” region; dVFR + residents; ‡all patients 
were German; §only hospitalized patients included in the study; #”33 months” reported in the study; NA: not applicable; NR: Not Reported. 
†percentages based on 121 patients, no data available about travel destination in one patient.
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fusion of a competent vector (Aedes albopictus) in 
several countries (Italy, southern France, Greece, 
Croatia, oriental part of Spain) [9, 11]. This is espe-
cially true for Milan city area, where both interna-
tional airports and high competent vector density 
(A. albopictus) coexist.
Nevertheless, autochthonous cases of Dengue 
have been reported only in Croatia, France and 
Spain so far [12-16]. Between 2013 and 2018, 
13.398 cases of imported DF were reported from 
27 countries in the European Union, 90.2% of 
which from seven countries: Germany (4428; 
36.6%), United Kingdom (2669; 22.1%), France 
(1507; 12.5%), Spain (1265; 10.5%), Sweden (935; 
7.7%), Belgium (649; 5.4%) and Italy (633; 5.2%) 
[18, 19]. 
We present 16-years data about epidemiological 
and clinical features of 122 cases of imported den-
gue fever observed at the Department of Infec-
tious Diseases of Luigi Sacco Hospital in Milan, 
Italy. The majority of patients were young tour-
ists of both genders. This is consistent with other 
Table 3 - European literature review - signs and symptoms.
Author, 
reference
Present 
work
Teichmann 
[20] 
Laferl 
[21] 
Lagi 
[28]
Trojanek 
[23]
Hoffmeister 
[24]
Tavakolipoor 
[25]
Calleri 
[26]
Kuna 
[27]
Riddell 
[29]
SIGNS/SYMPTOMS (%)
Fever 99.2 100 100 100 100 100 97.5 ~100e 43 95.4
Arthralgia 50.8 79 63 63.9a 59.8 21.4 42a ~70e NR 27.3a
Rash 50.8 66 43 41.7 68.2 46.4 47.9 ~50e 18.4 22.7
Headache 50.8 86 67 41.7 65.9 10.7c 49.6 ~60e 21.5 18.2
Myalgia 46.7 48 63 a 62.1 62.5% a NR 12.3 a
Nausea 26.2 14 34 63.9b NR NR NR NR 7.6 NR
Diarrhea 18 9 30 NR 36.4 NR 42.9 NR 15.5 22.7
Vomit 14.7 7 19 b 15.9 3.6d NR NR 9.2 22.7
Severe Dengue 0 1.4 8f 0 1 10.7g 0 0.9 0 2.3
aarthralgia and/or myalgia; bnausea and/or vomit; cretro-ocular pain; dpersistent vomiting; eprecise numeric values not reported, percentages ex-
trapolated from graphic; fDengue Hemorragic Fever (DHF) reported for 7 patients, Dengue Shock Syndrome (DSS) reported for 1 patient; gDSS 
reported for 2 patient; NR: data not reported.
Table 4 - European literature review: laboratory values.
Author, 
reference
Present 
work
Teichmann 
[20] 
Laferl 
[21] 
Lagi 
[28]
Trojanek 
[23]
Hoffmeister 
[24]
Tavakolipoor 
[25]
Kuna 
[27]
Riddell 
[29]
LABORATORY VALUES
Plt (median) 103 x103/µL 116 x103/µL 66 x103/µL NR 118 x103/µL NR NR 190 x103/µL 93 x103/µL
WBC (median) 2685/µL 2630/µL 2280/µL NR 3200/µL NR NR 5190/µL 4000/µL
Hct (median) 40.9% 43 U/L 43.9% NR 43.3% NR NR NR 41%
AST (median) 62 U/L 30 U/L 2.51xULN NR 70 U/L NR NR 60.4 U/L NR
ALT (median) 46 U/L 36 U/L 2.22xULN NR 85.3 U/L NR NR 50.8 U/L 67 U/L
LDH (median) 304 U/L NR 1.31xULN NR 294 U/L NR NR NR NR
Thrombocytopenia (%) 81.2 70 72 72.2 12.9a 84 32.8 20 NR
Leukopenia (%) 77.1 72 89 66.7 14.4b 73.2 26.1 24.6 NR
AST > ULN (%) 54.1 45 79 NR NR NR 32.8 23 NR
ALT > ULN (%) 45.9 41 70 NR NR NR 34.5 14 NR
LDH > ULN (%) 60.7 44 73 NR NR NR 31.1 NR NR
a<50x109/µL; b<2000/µL; Plt: platelets; WBC: white blood cells; AST: aspartate aminotrasferase; ALT: alanine aminotrasferase; LDH: lactate dehydro-
genase; ULN: Upper Limit of Normality; NR: data not reported.
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European experiences, except for the study pub-
lished by Lagi et al. (Italy) and Riddell et al. (UK), 
who observed a higher male prevalence [20-29]. A 
large proportion of patients (77%) became infect-
ed with DENV in Asia (Indian subcontinent and 
South-East Asia) and Central American/Caribbe-
an area (22%), in agreement with the results re-
ported in a recently published systematic review 
[30]. 
Seasonality in case occurrence reflects holiday 
season, with 43% of patients observed during 
August and September. This is also in agreement 
to the seasonality reported in Europe during the 
same years, with the notable exception of 2018 (a 
year not reported in our study), when the number 
of cases peaked in November [19]. 
It is also worth noticing that almost two-thirds 
(62,3%) of patients were observed in the period 
between June and October, when A. albopictus 
reaches the peak of its activity in our country [31]. 
In most of the patients (58.2%) the onset of symp-
toms occurred between 3 days before and 3 days 
after their return to Italy, reflecting both the short 
duration of travel and the brief incubation peri-
od of DF, which is usually 4 to 7 days [23]. More-
over, this high proportion of patients presenting 
during the acute phase of infection (thus poten-
tially viremic) may represent a potential risk for 
the development of an autochthonous transmis-
sion cycle in Europe, as suggested by similar 
results reported from a TropNet study [32]. The 
reasons why we didn’t yet witness a large au-
tochthonous outbreak of dengue in Southern Eu-
rope, where both permissive climatic factors and 
a competent vector are present, are still a matter 
of discussion, the main one possibly being that 
A. albopictus is a less competent DENV vector 
than A. aegypti (11). It must be noted, though, 
that both the introduction of a more competent 
vector and an improvement in efficiency of the 
present one (mainly through virus mutations) 
are concrete possibilities [33].
From a clinical point of view, DF must be differ-
entiated form other febrile illnesses, first of all 
malaria, and, in second place, Chikungunya and 
Zika fever [34]. Clinical symptoms are however 
very similar between DF and the aforementioned 
conditions, with a possible exception related to 
the frequency of skin rash and arthralgia. In our 
study maculopapular rash was observed in near-
ly half of patients, a frequency similar to the one 
reported in the majority of studies conducted in 
Europe, although two studies reported higher 
percentages (66-68%), while two others reported 
lower frequencies (21-22%) [20, 21, 23-29]. Skin 
rash is very rarely (if ever) observed in malaria, 
but it is, on the contrary, reported in 60-70% of pa-
tients diagnosed with Chikungunya and in more 
than 90% of those affected by Zika virus infection 
[35-40].
Arthralgia is by far more frequently encountered 
among patients with Chikungunya infection (83-
96%) and it is notably characterized by persis-
tence for several weeks in more than 30% of the 
patients [36, 39, 41, 42].
No patients fulfilled the criteria for severe den-
gue, in accordance to the majority of studies on 
imported DF, reporting less than 1% to no cases 
of severe DF; however, two studies (one of which 
used the previous dengue haemorragic fever/
dengue shock syndrome classification) reported 
severe dengue in 2.3% and 8% of cases, respec-
tively [20, 21, 23-29].
Consistent with other studies, diagnosis of den-
gue was established predominantly by antibody 
testing alone, with the majority of patients show-
ing positive IgM class antibodies at the time of first 
observation [25, 26, 28, 29]. It should be highlight-
ed, however, that the emergence and widespread 
diffusion of other arboviruses (suck as Zika and 
Chikungunya viruses), which frequently co-circu-
late in the same areas together with Dengue vi-
rus, makes the use of more specific tests (i.e., RT-
PCR) recommended in those patients presenting 
during the first five days of illness, together with 
serologies directed towards the above-mentioned 
viruses [43, 44]. Nevertheless, sensitivity limita-
tions of molecular tests and possible serological 
cross-reactivity might require additional eval-
uation by plaque reduction neutralization tests 
performed by reference laboratories to correctly 
diagnose some case [44, 45]. Our study presents 
several limitations, the retrospective single-center 
design being the most relevant. Another potential 
limitation is that the majority of our study sub-
jects were diagnosed with “probable” DF, which 
could have led to false positive diagnosis because 
of the relatively low specificity of serology alone. 
In conclusion, according to our study, the “typi-
cal patient” with dengue fever is a young tourist, 
returning from a tropical area (more often from 
South-East Asia or the Caribbean/Central Amer-
251Imported dengue fever
ican area), presenting with fever associated with 
thrombocytopenia and leukopenia.
Awareness, early recognition and notification are 
fundamental, since importation and local trans-
mission in Italy are concrete possibilities due to 
the presence of a competent vector. A prompt di-
agnostic approach to dengue in settings of high 
clinical and epidemiological suspicion, as well 
as the improvement of surveillance programs 
should be carried out to properly identify a possi-
ble autochthonous outbreak.
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